Company intelligence / Profile preview

Diaster

India

Ownership: Private
Development stage: Other

Overview

Stermed India is a pharmaceutical company based in India that focuses on the development and commercialization of specialized medications for joint health and pain management. The company is best known for its product Diaster M, a combination therapy containing diacerein, glucosamine sulfate, and methylsulfonylmethane (MSM) used to treat osteoarthritis. Diaster M works by stimulating proteoglycan synthesis and reducing joint inflammation and friction to improve mobility. Stermed India provides a range of analgesic and anti-inflammatory products aimed at restoring cartilage and managing chronic joint disorders.

Therapeutic areas: Rheumatology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Diaster.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diaster.

Explore the full profile